Who is eligible to receive a bispecific antibody?

All FDA-approved bispecific antibody therapies (as of July 2024) are approved for relapsed and refractory multiple myeloma patients. 

For context, refractory means that the therapy previously being used in your treatment is no longer working, and your myeloma is actively increasing. Relapse means that the disease responds to previous medication and the treatment has been adjusted accordingly (for example, you start a lower-dose maintenance therapy or you stop treatment), and then the myeloma returns. 

The type and number of therapies that you previously received and how your disease responded to them will inform if a bispecific antibody therapy is the best for you and which one. View current eligibility criteria in this section: FDA-Approved Bispecific Antibodies 

If you do not meet these criteria but wish to receive bispecific antibody therapy, consider an open clinical trial. Ask your treating medical team for more information or explore the HealthTree Myeloma Clinical Trial Finder.

There is no optimal age to receive bispecific antibody therapy. However, functionality and physical health, as well as comorbidities, such as diabetes or high blood pressure, may play a role in which treatments are available and safe for you.